Target intelligence / Profile preview

Kirsten rat sarcoma virus oncogene homolog messenger RNA G-quadruplex in the 5'-untranslated region (KRAS 5'-UTR G4)

Target
KRAS 5'-UTR G4
Molecular classification
Nucleic acid, RNA secondary structure, G-quadruplex
01

Overview

The Kirsten rat sarcoma virus oncogene homolog (KRAS) mRNA G-quadruplex in the 5'-untranslated region (5'-UTR) is a complex four-stranded secondary structure formed by guanine-rich sequences (Cogoi et al., 2010, J Biol Chem). This structural element serves as a critical regulatory node in the post-transcriptional control of KRAS expression, a protein that functions as a molecular switch in signaling pathways governing cell growth and survival. In the context of oncology, KRAS is one of the most frequently mutated oncogenes, particularly in pancreatic, colorectal, and lung cancers, where it drives aggressive tumor progression (Xodo et al., 2016, Expert Opin Ther Targets). Therapeutic strategies targeting this G-quadruplex involve the use of small-molecule ligands, such as naphthalene diimide derivatives, that bind and stabilize the structure (Cogoi et al., 2014, Nucleic Acids Res). This stabilization creates a steric hindrance that prevents the 40S ribosomal subunit from scanning the mRNA, effectively silencing the translation of the KRAS oncogene. This approach provides a mutation-agnostic strategy to inhibit KRAS signaling, potentially addressing a wide range of KRAS-driven malignancies that are otherwise difficult to treat.

Other names
KRAS mRNA G-quadruplexKRAS 5'-UTR G-quadruplexKRAS G4 structure
02

Mechanism of action

Stabilization of the G-quadruplex structure within the 5'-untranslated region of KRAS mRNA to sterically inhibit ribosomal scanning and subsequent protein translation (Cogoi et al., 2010, J Biol Chem; Xodo et al., 2016, Expert Opin Ther Targets).

03

Biological functions

Translation regulationPost-transcriptional gene regulationmRNA stability control
04

Disease associations

CancerPancreatic adenocarcinomaColorectal cancerNon-small cell lung cancer
05

Safety considerations

Off-target binding to other genomic or transcriptomic G-quadruplexes (e.g., MYC, BCL2, or telomeric G4s)Potential for systemic toxicity due to broad stabilization of G-quadruplexes across the transcriptomeInhibition of translation for essential genes containing similar G-rich motifs
06

Interacting drugs

TMPyP4

4 more in the full profile.

07

Biomarkers

KRAS mutation status (e.g., G12D, G12V, G12C)KRAS protein expression levelsG-quadruplex ligand occupancy

Beyond the preview

Go deeper on Kirsten rat sarcoma virus oncogene homolog messenger RNA G-quadruplex in the 5'-untranslated region (KRAS 5'-UTR G4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kirsten rat sarcoma virus oncogene homolog messenger RNA G-quadruplex in the 5'-untranslated region (KRAS 5'-UTR G4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call